Introduction {#Sec1}
============

Breakthrough pain is prevalent (41--95%) among patients with cancer \[[@CR1], [@CR2]\] and presents challenges to effective pain management \[[@CR2], [@CR3]\]. Breakthrough pain typically exhibits a rapid onset (typically \<5 min, ranging from 1 s to 30 min until peak intensity), severe intensity, and lasts for \<1 h, but may last for up to 1 to 2 h \[[@CR4], [@CR5]\]. Therefore, optimal relief from breakthrough pain is best attained by administering analgesics which have pharmacokinetics and pharmacodynamics that closely match the time course of breakthrough pain events.

The transmucosal route of administration of analgesics can avoid first-pass hepatic metabolism and allow rapid entry of drugs into the systemic circulation \[[@CR6], [@CR7]\]. It can also yield increased bioavailability relative to orally administered drugs \[[@CR8]\]. Current clinical guidelines recommend transmucosal fentanyl as an option for the relief of breakthrough cancer pain \[[@CR9]\]. A variety of transmucosal fentanyl products with different routes of administration (e.g., lozenge, buccal tablet, buccal film, sublingual tablet, sublingual spray, and nasal spray) are available. A novel sublingual tablet form of fentanyl (Abstral^®^; Galena Biopharma, Portland, OR, USA) was developed that would undergo rapid disintegration and absorption within the time of onset and duration of breakthrough pain \[[@CR10]\].

The subjective nature of pain is reflected in the highly variable and individualized responses to pain therapies. Patient perception of "dwell time" contributes to preference, which in turn can affect compliance rates \[[@CR11]\]. Previous studies have demonstrated the efficacy of sublingual fentanyl tablets in the treatment of breakthrough pain in patients who are opioid tolerant \[[@CR12], [@CR13]\]. Preliminary assessments of the disintegration time and patient acceptability of this fentanyl formulation have been previously presented \[[@CR14]--[@CR16]\]. Here, we present a detailed assessment of patient perception of the complete disintegration time of sublingual fentanyl tablets in practice-based, opioid-tolerant patients. Measurement of pain relief was not an objective of this study.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

Men and women aged 18--75 years with chronic pain who were tolerant to opioids (i.e., morphine 60 mg/day or equivalent for ≥1 week) were eligible for enrollment in the study. Women of child-bearing potential had to be using an acceptable form of birth control to participate in the study. Exclusion criteria included: allergy to fentanyl or its derivatives; history of severe chronic obstructive pulmonary disease; or asthma that, in the investigator's opinion, was medically significant. Pregnant or lactating women and patients deemed by the investigator to be medically unstable were also excluded from the study.

Study Design {#Sec4}
------------

This single-center, non-randomized, open-label study was designed to enroll a minimum of 10 patients in each of 3 dose groups. The primary objective was to assess patient-reported time for complete disintegration of 3 different doses of sublingual fentanyl oral disintegrating tablets in opioid-tolerant patients. The design of the study was approved by an independent institutional review board (Ethical and Independent Review Committee, Inc., Independence, MO, USA) and the study was conducted in accordance with US Food and Drug Administration regulations for the conduct and monitoring of clinical investigations. Procedures were in accordance with Good Clinical Practice and International Conference on Harmonisation guidelines, and with the Declaration of Helsinki of 1975, as revised in 2000 and 2008. All patients provided written informed consent before initiation of study procedures.

During the training phase, patients were given a placebo matching the sublingual fentanyl tablet to ensure optimal sublingual placement of the tablet and to establish familiarity with the product dissolution and assessment of disintegration time. During the subsequent evaluation phase, each patient self-administered a single 100, 200, or 300 μg sublingual fentanyl tablet. Patients received the appropriate dose of study drug (as determined by the investigator) in an outpatient setting; all patients who were naive to rapid-acting fentanyl received sublingual fentanyl 100 μg. Patients being treated with other rapid-acting fentanyl products \[e.g., Actiq^®^ (fentanyl citrate oral transmucosal lozenge; Cephalon, Inc., Frazer, PA, USA), Fentora^®^ (fentanyl citrate buccal tablet; Cephalon, Inc., Frazer, PA, USA), or Onsolis^®^ (fentanyl buccal soluble film; Meda Pharmaceuticals, Inc., Somerset, NJ, USA)\] were given the equivalent of 50% of their dose at that time, to the nearest lower strength of sublingual fentanyl (not to exceed 300 μg).

Patients were permitted to use all concurrent medications, including long-acting opioids, for the duration of this study. However, patients were instructed not to use other forms of rapid-acting fentanyl, including Actiq, Fentora, Onsolis, or Abstral, for breakthrough pain for 2 h before and after the administration of study drug \[[@CR17]--[@CR20]\]. Adherence to this requirement was independently confirmed by study personnel.

Assessments {#Sec5}
-----------

Time to complete disintegration was defined as the time post-administration when the patient felt that the sublingual tablet had completely dissolved under the tongue, as measured by each patient with a stopwatch and independently verified by study personnel. Any adverse events (AEs) believed to be expected or unexpected, whether reported by the patient or noted by the investigator, were to be recorded.

Statistical Methods {#Sec6}
-------------------

Descriptive statistics were used to summarize pooled data from the individual treatment groups. Analyses were performed using Prism v5.04 (GraphPad Software, Inc., La Jolla, CA, USA). One-way analysis of variance (ANOVA), followed by the Bonferroni post hoc test, was used to compare the total disintegration times among the groups administered the 3 strengths of sublingual fentanyl. A 2-tailed unpaired *t* test was used to assess the difference in disintegration time between men and women across all doses of sublingual fentanyl. Linear regression analysis was used to assess the effects of age on disintegration time across all doses of sublingual fentanyl.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

Pooled baseline demographics of patients in all treatment groups are summarized in Table [1](#Tab1){ref-type="table"}. The mean age for all patients in this study was 54 years (range 36--74 years) with more women (18/30; 60%) than men. Maintenance and breakthrough pain treatments for the study population are listed in Table [2](#Tab2){ref-type="table"}.Table 1Key baseline demographic characteristicsCharacteristicsPatients (*N* = 30)Sex, *n* (%) Men12 (40.0) Women18 (60.0)Mean age, years (range) All patients54 (36--74) Men52 (36--74) Women56 (38--74)Table 2Analgesic treatment historyPatients (*N* = 30)Maintenance treatment, *n* (%) Fentanyl transdermal system8 (27) Methadone3 (10) Oxycodone controlled release3 (10) Fentanyl2 (7) Hydrocodone and acetaminophen2 (7) Hydromorphone extended release2 (7) Morphine sulfate controlled release or extended release2 (7) Oxycodone2 (7) Oxymorphone extended release2 (7) Buprenorphine transdermal system1 (3) Hydromorphone1 (3) Pregabalin1 (3) Tizanidine1 (3)Breakthrough pain treatment, *n* (%) Fentanyl buccal tablet12 (40) Fentanyl oral transmucosal lozenge6 (20) Fentanyl sublingual tablet2 (7) Hydrocodone and acetaminophen2 (7) Oxycodone2 (7) Oxymorphone immediate release2 (7) Buprenorphine1 (3) Morphine sulfate extended release1 (3) Oxycodone and acetaminophen1 (3) Tramadol extended release1 (3)

Disintegration Time of Sublingual Fentanyl {#Sec9}
------------------------------------------

The disintegration time (mean ± SD) for the sublingual placebo used during training was 107.1 ± 73.4 s. The disintegration time for sublingual fentanyl across all doses was 88.2 ± 55.1 s; there was a non-significant trend toward longer disintegration times for the 200 μg (96.7 ± 57.9 s) and 300 μg (98.6 ± 64.8 s) sublingual fentanyl doses compared with the 100 μg sublingual fentanyl dose (69.5 ± 40.5 s; Fig. [1](#Fig1){ref-type="fig"}). Disintegration time for sublingual fentanyl across all doses was similar between men and women (Fig. [2](#Fig2){ref-type="fig"}), and was not affected by age (Fig. [3](#Fig3){ref-type="fig"}). No AEs occurred during the study.Fig. 1Complete disintegration time of sublingual fentanyl as a function of dose. One-way analysis of variance among 3 dose groups of sublingual fentanyl (*P* = 0.4313)Fig. 2Complete disintegration time of sublingual fentanyl as a function of sex (unpaired *t* test, *P* = 0.4090)Fig. 3Complete disintegration time of sublingual fentanyl as a function of age (linear regression, *P* = 0.3552)

Discussion {#Sec10}
==========

The persistently high prevalence of breakthrough pain in patients with cancer indicates an ongoing need for rapidly acting analgesics with pharmacokinetic properties that match the rapid onset and short duration of breakthrough pain \[[@CR21], [@CR22]\]. Although several rapid-acting fentanyl analgesics \[Abstral, Actiq, Fentora, Onsolis, Subsys^®^ (fentanyl sublingual spray; INSYS Therapeutics, Inc., Chandler, AZ, USA), and Lazanda^®^ (fentanyl nasal spray; Depomed, Newark, CA, USA)\] are currently available, these products are not therapeutically interchangeable, and there may be considerable differences in patient preferences \[[@CR17]--[@CR20], [@CR23], [@CR24]\]. Sublingual fentanyl, with a novel mucoadhesive, is an effective analgesic for the management of breakthrough cancer pain \[[@CR12], [@CR13]\]. In the present study, sublingual fentanyl exhibited rapid disintegration times and high levels of bioavailability consistent with the ease of administration of this form of fentanyl.

Perceptions of disintegration time (or "dwell time") could be a factor in patient preference, although direct evidence is currently lacking. Several earlier generation fentanyl products currently used for the relief of breakthrough pain employ different methods of drug delivery (e.g., lozenge, buccal tablet, film) and should be held in the mouth for approximately 15--30 min to achieve drug dissolution \[[@CR17]--[@CR19]\]. These relatively long dwell times may not be optimal for the relief of breakthrough pain. The present study assessed the patient's perception of complete disintegration time and taste of 3 doses (100, 200, or 300 μg) of rapid-acting sublingual fentanyl. The results showed that sublingual fentanyl rapidly disintegrated, with the time to patient-reported complete disintegration ranging from 69.5 s in the 100 μg dose group to 98.6 s in the 300 μg dose group. Although there were no significant differences in disintegration time between sublingual fentanyl dose groups, this study was not powered for statistical analysis. The mean disintegration time across all doses of sublingual fentanyl did not differ significantly by age or sex. Patients in this study were exposed to placebo tablet training prior to sublingual fentanyl administration. Using a sublingual placebo tablet to familiarize patients with optimal placement of the drug and perception of its complete disintegration may be a useful component of individualized care in the management of breakthrough cancer pain \[[@CR25]\].

Effective treatment of breakthrough cancer pain may be influenced by patient acceptance of the drug, and it is important to note that the present study focused on disintegration time and not pain relief. In addition, the open-label, non-randomized design of this study limits the conclusions that can be drawn. Furthermore, the study did not include crossover to a comparator treatment such as a matching placebo sublingual tablet or a different transmucosal fentanyl product. Finally, the small sample size of this study may not have provided adequate statistical power to detect differences between groups. Therefore, additional studies are needed to assess the degree to which disintegration time is of practical importance in the willingness of patients to switch from their current treatment to sublingual fentanyl.

Conclusions {#Sec11}
===========

Sublingual fentanyl tablets of all doses dissolved rapidly, with an average time to complete disintegration of \<2 min. This compares very favorably to other solid forms of transmucosal immediate release fentanyl, each having dwell times of approximately 15--30 min until complete disintegration.
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